Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | PKN1 | Q16512 | 4/20 | 0.59 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RHEB | Q15382 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ridinilazole SCHEMBL413723 | 0.87 | ALDH1A1 (0.66) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| Ridinilazole SCHEMBL29379856 | 0.87 | ALDH1A1 (0.66) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL19994736 | 0.83 | AURKA (0.59) | KDM4ENPC1RAB9AGUSBCHEK2 | |
| SCHEMBL16498271 | 0.83 | NPC1 (0.63) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL30343733 | 0.83 | AURKA (0.59) | KDM4ENPC1RAB9AGUSBCHEK2 | |
| Ridinilazole SCHEMBL17867397 | 0.81 | NPC1 (0.65) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL16498509 | 0.80 | KDM4E (0.57) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL16499476 | 0.79 | ALDH1A1 (0.65) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL22906080 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL6263502 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KDM4EPKN1PKN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| CN-110234640-B | Benzimidazole derivatives as anticancer agents | 利昂贝拉尔中心 | 2023-04-07 | — | — | CN | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3515904-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | Centre Leon Berard (FR) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CCAR2, MAPKAP1, BCOR | ALDH1A1 3500/4885KDM4E 4285/4885PKN1 2537/4885 |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | TMBIM6, BAX, MAPK14 | ALDH1A1 2866/4885KDM4E 1838/4885PKN1 796/4885 |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | TMBIM6, BAX, MAPK14 | ALDH1A1 2866/4885KDM4E 1838/4885PKN1 796/4885 |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | TMBIM6, BAX, BCL2 | ALDH1A1 2871/4885KDM4E 1858/4885PKN1 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.